# Pizarra — PT-pseudo_249def42388a (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_249def42388a
Task: 1

Encounter: Urology - outpatient on 20 Feb 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 78-year-old male
  - PSA: 7.6 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.236 ng/mL²
  - PSA velocity: 0.84 ng/mL/yr
  - Prior PSA: 5.7 ng/mL
  - Prostate volume: 32.25 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.82135016 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes
  - Problem list / PMHx: Type 2 diabetes
  - Current medication: empagliflozin
  - Allergies: NKA
  - Additional notes: PSA 7.6 ng/mL. PI-RADS 5. PSAD 0.24. Prostate volume 32 mL. DRE nodus. csPCa 0.82.

Vitals: weight 104 kg, height 190 cm, BMI 28.8, BP 136/96 mmHg, HR 64 bpm. Smoking: Current smoker (29 pack-yr).

Chief complaint: Persistent PSA elevation alongside recent multiparametric MRI results prompted this clinical evaluation.

History: Now 78 years old, this widowed civil engineer recently retired and moved to the region half a year ago. He shares a home with his sister, while his adult son handles daily logistics and serves as his lasting power of attorney. His prior biopsy bucket remains "None". Lower urinary tract complaints are entirely absent, yielding an IPSS score of zero, and he explicitly denies pelvic discomfort or blood in the urine. His medical background includes well-regulated type 2 diabetes, currently treated with empagliflozin under quarterly diabetes nurse supervision. A substantial 29 pack-yr smoking history is noted, alongside a moderate alcohol consumption pattern of twelve units weekly. He swims once a week to stay fit. Stable osteoarthritis in his right knee is managed with paracetamol, and he recalls a minor appendectomy during his twenties. Otherwise, he reports feeling generally robust.

Physical examination: DRE — texture: firm with a discrete Nodus localized to the left peripheral zone; asymmetry: clearly present. General examination remains unremarkable, recording a blood pressure of 136/96 mmHg, a heart rate of 64 bpm, and a body mass index of 28.8. No abdominal masses or peripheral lymphadenopathy are detected.

Patient info: civil engineer; Widowed; Recently relocated; lives with sister.
Next of kin: Adult son (acts as caregiver, lasting power of attorney).

Lifestyle: alcohol 12 units / week; exercise Swimming 1x/week; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Diabetes nurse — quarterly review.
Admin: Interpreter: not required. Consent for data use: signed.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.77 +/- 0.17   (95% CI 0.37-0.99)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.07  (few labelled cases resemble this one)
  - 4.6 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'supports': A +/- dA does not cross 0.5, but A +/- 1.96*dA does. There is a direction, not a conclusion. Measured accuracy in this tier: 0.67. Treat it as a weighted vote, not as a decision.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=7.6, age=78.0, psad=0.236, dre_ord=1.0, vol=32.25, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical recommender only used the visible panel data (PI-RADS=5.0, PSA=7.6, Age=78, PSA Density=0.236, DRE=Nodus, Volume=32.25 mL, N_PMHx=1.0) and could not account for the PSA velocity (0.84 ng/mL/yr), the specific context of the PI-RADS 5 score in relation to the guideline's risk matrix, or the absence of any retrieved MRI report or PSA history.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy based on a high probability (0.77), but the guideline criterion is based on PI-RADS $\ge 3$, which is met, but the guideline also suggests omitting biopsy if PSA density is $< 0.10 \text{ ng/mL/cc}$ and there is no family history, which is not fully assessed by the prior. The prior's wide uncertainty interval ($0.17$) suggests the model is highly uncertain, which could mean the true decision is closer to the deferral threshold. Furthermore, the prior does not account for the PSA velocity or the specific context of the PI-RADS 5 score relative to the guideline's risk stratification.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes
laboratory panel

GUIDELINE ANCHOR
The guideline states that a PI-RADS $\ge 3$ score is used to trigger biopsy, but it also suggests omitting biopsy if the PSA density is $< 0.10 \text{ ng/mL/cc}$ and there is no family history.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Radiology Division | Catharina Ziekenhuis, Eindhoven | 28 Jan 2025 | Multiparametric MRI Prostate
PI-RADS: 5 lesion in the left peripheral zone (base/mid), approximately 18 mm.
csPCa probability: 0.82135016.

get_psa_trend
PSA trend shows a rising trajectory: 0.6 (Jul 2022) -> 2.0 (Mar 2023) -> 3.0 (Oct 2023) -> 5.9 (Jun 2024) -> 7.6 (Feb 2025).

get_previous_notes
03 Mar 2023: "Subsequent visit to review initial screening PSA outcomes. Laboratory data showed a PSA level of 4.3 ng/mL, marking a steady rise from the 4.0 ng/mL measurement documented in July 2022. Diabetes care was reassessed, with empagliflozin therapy maintained."

get_lab_results
PSA: 7.6 ng/mL (05 Feb 2025).
%Free PSA: 16% (05 Feb 2025).
eGFR: >60 mL/min/1.73m2 (05 Feb 2025).

NOT RETRIEVED
The family history of prostate cancer anamnesis was not retrieved, which is needed to assess the guideline criterion regarding PSA density and family history.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 5 lesion (18 mm) in the left peripheral zone, with a csPCa probability of 0.82135016.
- PSA trend: Clear rising trajectory from 0.6 ng/mL in Jul 2022 to 7.6 ng/mL in Feb 2025.

AGAINST sampling this patient now:
- Lab results: %Free PSA is 16% (which is not explicitly $< 10\%$, but the guideline condition is complex).

WHERE THIS LEANS
The evidence strongly supports biopsy due to the high-risk PI-RADS 5 score and the significant, rising PSA velocity, aligning with the expert protocol's criterion for biopsy when PI-RADS is 3 or higher.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the mpMRI revealed a PI-RADS 5 lesion, which is the primary driver for sampling according to the expert protocol. This finding was supported by the rising PSA trajectory, which was retrieved from the evidence report. The statistical prior suggested biopsy, and the retrieved evidence converged with the guideline criterion, leading to a clear recommendation.

Variables that carried weight: age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
